Bifogade filer
Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STOCKHOLM, Sweden, 19th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached “Database Lock” in its clinical development program. The next step is statistical analyses of the data to compile the results. Lipidor will publish the primary results during the last week of May, according to the previously communicated timeline.
The primary goal of the study is to demonstrate good therapeutic effect for the treatment of mild to moderate psoriasis on both the body and the scalp. The psoriasis candidate AKP02G2 combines calcipotriol and betamethasone dipropionate and is based on Lipidor’s patented AKVANO® technology. Lipidor has chosen to compare the sprayable drug candidate AKP02G2 with Enstilar, which is a market-leading preparation for topical treatment for psoriasis. AKP02G2 contains the same combination of active substances as Enstilar. After the database closing, unblinding will carried out so that Cliantha statisticians can conduct analysis of the study's results.
“We are pleased to announce that our Phase III study with the psoriasis candidate AKP02G2 has reached database lock and we look forward to presenting the primary results from the study before the end of May," says Ola Holmlund, CEO, Lipidor AB.
Publication
The information was provided by Lipidor’s CEO for publication on 19th May at 8.30am (CEST).